Last reviewed · How we verify
daclizumab, infliximab
daclizumab, infliximab is a Monoclonal antibody combination Small molecule drug developed by University of Iowa. It is currently FDA-approved for Multiple sclerosis (daclizumab component), Rheumatoid arthritis and inflammatory bowel disease (infliximab component).
This is a combination of two monoclonal antibodies: daclizumab blocks IL-2 receptor alpha on T cells to reduce immune activation, while infliximab blocks TNF-alpha to suppress inflammatory cytokine signaling.
This is a combination of two monoclonal antibodies: daclizumab blocks IL-2 receptor alpha on T cells to reduce immune activation, while infliximab blocks TNF-alpha to suppress inflammatory cytokine signaling. Used for Multiple sclerosis (daclizumab component), Rheumatoid arthritis and inflammatory bowel disease (infliximab component).
At a glance
| Generic name | daclizumab, infliximab |
|---|---|
| Sponsor | University of Iowa |
| Drug class | Monoclonal antibody combination |
| Target | IL-2 receptor alpha (CD25) and TNF-alpha |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Daclizumab is an IL-2 receptor antagonist that selectively depletes activated T cells, particularly CD25+ cells involved in autoimmune responses. Infliximab is a TNF-alpha inhibitor that blocks a key pro-inflammatory cytokine. Together, they provide dual immunosuppression targeting different pathways of immune activation and inflammation.
Approved indications
- Multiple sclerosis (daclizumab component)
- Rheumatoid arthritis and inflammatory bowel disease (infliximab component)
Common side effects
- Infections (including serious infections)
- Infusion reactions
- Hepatotoxicity
- Autoimmune hepatitis (daclizumab)
Key clinical trials
- Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD (PHASE4)
- Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration (PHASE2)
- Multicenter Uveitis Steroid Treatment (MUST) Trial (PHASE4)
- A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- daclizumab, infliximab CI brief — competitive landscape report
- daclizumab, infliximab updates RSS · CI watch RSS
- University of Iowa portfolio CI
Frequently asked questions about daclizumab, infliximab
What is daclizumab, infliximab?
How does daclizumab, infliximab work?
What is daclizumab, infliximab used for?
Who makes daclizumab, infliximab?
What drug class is daclizumab, infliximab in?
What development phase is daclizumab, infliximab in?
What are the side effects of daclizumab, infliximab?
What does daclizumab, infliximab target?
Related
- Drug class: All Monoclonal antibody combination drugs
- Target: All drugs targeting IL-2 receptor alpha (CD25) and TNF-alpha
- Manufacturer: University of Iowa — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Multiple sclerosis (daclizumab component)
- Indication: Drugs for Rheumatoid arthritis and inflammatory bowel disease (infliximab component)
- Compare: daclizumab, infliximab vs similar drugs
- Pricing: daclizumab, infliximab cost, discount & access